Gale­na im­plodes as tri­al mon­i­tors call a halt to a failed PhI­II can­cer study

Shares of Gale­na ($GALE) were evis­cer­at­ed this morn­ing, drop­ping 78% af­ter the biotech an­nounced that it had stopped a Phase III study of its lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA